BMS wins approval for kidney transplant drug; Biogen mulls HQ move back to Cambridge;

@FiercePharma: Sanofi moves deeper into Genzyme operations. Item | Follow @FiercePharma

> Bristol-Myers Squibb got the FDA nod for Nulojix, its new drug to prevent organ rejection in adult patients who have undergone a kidney transplant. Story

> Biogen Idec is considering options to move its headquarters back from the suburbs to Cambridge, MA, as CEO George Scangos seeks to foster a more close-knit culture between the company's R&D and commercial operations. News

> Stada aims to expand outside its German home market by making acquisitions and could use proceeds from another bond to finance any big deals, the generic drugmaker's chief executive said. Report

> FDA accepted Novartis' application to broaden use of its meningitis vaccine Menveo, the Swiss drugmaker said, giving its vaccines and diagnostics unit another boost. Story

> A vaccine that prevents the most common cause of severe diarrhea and dehydration in babies was associated with a potentially life-threatening bowel disorder in a large study from Mexico and Brazil, but the risk was small. Item

> A vaccine developed by Serum Institute of India, led by billionaire Cyrus Poonawalla, was better at protecting people from a strain of meningitis in sub-Saharan Africa than older products from companies including GlaxoSmithKline, researchers said. Article

Biotech News

@FierceBiotech: Cancer drug collaborations are hot. Story | Follow @FierceBiotech

@JohnCFierce: Interesting Xconomy piece on Somnus, but de-risked sleep meds relying on new delivery tech just looks weak to me. News | Follow @JohnCFierce

> Will new drug partnerships force a fresh take on costs? Story

> AstraZeneca to predict drug safety at Russian R&D center. Item

> Sanofi puts "open innovation" game plan to work on hearing loss. Report

> Bristol-Myers on a roll as it snags an approval for belatacept. Article

Vaccines News

> Immatics starts late-stage cancer vaccine study. News

> Type I diabetes nasal vaccine on the horizon. Item

> GSK boosts China presence with flu vaccine buyout. Story

> BiondVax releases promising Ph2 universal flu vax results. Article

> Cheap meningitis vax beats out GSK's version. Story

> GSK, Arecor form vaccine stabilization pact. Article

Manufacturing News

> Expert: FDA inadvertantly causing drug shortages. News

> APP expansion could help fight against drug shortages. Item

> Dr. Reddy's tarnished by FDA warning, fire probe. Story

> GSK deals to boost vax stability, fight flu in Asia. Report

> Fidelity mutual fund rides big pharma profits. Item

And Finally... Purdue Pharma, the maker of OxyContin, may have succeeded for now in reducing illicit demand for its reformulated drug. Report

Suggested Articles

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.

A patent decision in Delaware clears the way for multiple generic companies to launch their Tecfidera copycats—and target its $3.3B in U.S. sales.

Sanofi and GlaxoSmithKline signed a deal with the EU to supply up to 300 million doses of their recombinant protein-based COVID-19 vaccine.